Table 2 Demographic characteristics and other reference values
Number of patients | PD patients with pruritus resistant to existing treatments (N = 37) | |
|---|---|---|
Sex | Male | 27 (73.0%) |
Female | 10 (27.0%) | |
Age (year) | 63.5 ± 9.1 | |
Weight(kg) | 63.14 ± 11.03 | |
Primary disease | Glomerulonephritis | 15 (40.5%) |
Diabetic nephropathy | 15 (40.5%) | |
Renal failure, unspecified | 1 (2.7%) | |
Other | 6 (16.2%) | |
Type of dialysis solution | Dextrose and icodextrin solutions, or icodextrin solution alone | 17 (45.9%) |
Dextrose solution | 20 (54.1%) | |
Type of peritoneal dialysis | CCPD (with APD) | 13 (35.1%) |
CAPD (without APD) | 24 (64.9%) | |
Duration of peritoneal dialysis (year) | 2.30 ± 2.33 | |
With anamnesis | 20 (54.1%) | |
With complications | 37 (100.0%) | |
Duration of itching (year) | 1.76 ± 2.20 | |
Mean VAS score in week 2 in the pretreatment period observation (mm) (the larger of the score upon rising or before bed) | 77.22 ± 11.46 | |
Mean itch score based on Shiratori’s severity criteria in week 2 in the pretreatment period observation (the larger of the score upon rising or before bed) | 3.11 ± 0.37 | |
Pruritus treatments used within 1 year before the informed consent acquisition date | ||
Oral drug | Antihistamines or antiallergics | 37 (100.0%) |
Steroid | 0 (0.0%) | |
Other | 0 (0.0%) | |
Total | 37 (100.0%) | |
Topical product | Antihistamines or antiallergics | 11 (29.7%) |
Steroid | 12 (32.4%) | |
Moisturizing agents | 27 (73.0%) | |
Other | 11 (29.7%) | |
Total | 37 (100.0%) | |
Injection product | Antihistamines or antiallergics | 0 (0.0%) |
Steroid | 0 (0.0%) | |
Stronger neo-minophagen C | 0 (0.0%) | |
Other | 0 (0.0%) | |
Total | 0 (0.0%) | |
Pruritus treatments used during clinical trial | ||
Oral drug | Antihistamines or antiallergics | 34 (91.9%) |
Steroid | 0 (0.0%) | |
Other | 0 (0.0%) | |
Total | 34 (91.9%) | |
Topical product | Antihistamines or antiallergics | 7 (18.9%) |
Steroid | 11 (29.7%) | |
Moisturizing agents | 24 (64.9%) | |
Other | 12 (32.4%) | |
Total | 37 (100.0%) | |
Injection product | Antihistamines or antiallergics | 0 (0.0%) |
Steroid | 0 (0.0%) | |
Stronger neo-minophagen C | 1 (2.7%) | |
Other | 0 (0.0%) | |
Total | 1 (2.7%) | |
Pruritus-related factors in CKD patients | ||
Complications (overlapping) | Hyperphosphatemia | 28 (75.7%) |
Secondary hyperparathyroidism | 27 (73.0%) | |
Asteatosis | 3 (8.1%) | |
Hypocalcemia | 1 (2.7%) | |
Xeroderma | 1 (2.7%) | |
Immunodeficiency | 1 (2.7%) | |
Laboratory value (pretreatment value) | Mean plasma hemoglobin (g/dL; ± SD) | 10.58 ± 1.33 |
Mean plasma eosinophils (%; ± SD) | 7.43 ± 6.54 | |
Mean serum albumin (g/dL; ± SD) | 3.49 ± 0.40 | |
Mean plasma hematocrit (%; ± SD) | 31.98 ± 4.22 | |
Mean serum urea nitrogen (mg/dL; ± SD) | 56.2 ± 14.1 | |
Mean serum creatinine (mg/dL; ± SD) | 9.953 ± 3.179 | |
Mean serum phosphorus (mg/dL; ± SD) | 5.18 ± 1.10 | |
Mean serum calcium (mg/dL; ± SD) | 8.85 ± 0.89 | |